GRP78 acts as a promising target for AML CAR T-cell therapy due to its normal residence in the endoplasmic reticulum in healthy cells and stress-induced transportation to the cell surface when a cell undergoes tumorigenesis. Here, HSPA5 is linked to acute myeloid leukemia.